Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings

Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings

Background: Human albumin (HA) is an effective adjuvant treatment for patients with cirrhosis developing spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS) and ascites requiring large-volume paracentesis (LVP). However, cost remains a barrier to use, particularly in resource-limited...

Full description

Bibliographic Details
Main Authors: Irsan Hasan, Ignatia Sinta Murti, Putut Bayupurnama, Kemal Fariz Kalista, Christina Hill-Zabala, Dennis Kananda, Elisabet Viayna
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2024-04-01
Series:Drugs in Context
Subjects:
cost-effectiveness
human albumin
indonesia
liver cirrhosis
liver diseases
resource-limited settings
Online Access:https://www.drugsincontext.com/cost-effectiveness-of-albumin-in-the-treatment-of-decompensated-cirrhosis-in-resource-limited-healthcare-settings/

Internet

https://www.drugsincontext.com/cost-effectiveness-of-albumin-in-the-treatment-of-decompensated-cirrhosis-in-resource-limited-healthcare-settings/

Similar Items